Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

49 results about "Tumid Lupus Erythematosus" patented technology

Tumid lupus erythematosus is a rare, but distinctive entity in which patients present with edematous erythematous plaques, usually on the trunk. Lupus erythematosus tumidus (LET) was reported by Henri Gougerot and Burnier R. in 1930. It is a photosensitive skin disorder, a different subtype of cutaneous lupus erythematosus (CLE) from discoid lupus erythematosus (DLE) or subacute CLE (SCLE). LET is usually found on sun-exposed areas of the body. Skin lesions are edematous, urticarialike annular papules and plaques. Topical corticosteroids are not effective as treatment for LET, but many will respond to chloroquine. LET resolves with normal skin, no residual scarring, no hyperpigmentation or hypopigmentation. Cigarette smokers who have LET may not respond very well to chloroquine.

Application of coptisine in preparing medicine for preventing and/or treatingSLE (systemic lupus erythematosus) and complications of SLE

The invention discloses application of coptisine shown as general formula (I) as shown in the specification and pharmaceutically acceptable salt of the coptisine in preparing a medicine for preventing and/or treatingSLE (systemic lupus erythematosus) and complications of SLE.The application has the benefits that the coptisine has pharmacological actions of reducing an in-vivo autoantibody expression level of a mouse with lupus, improving an immunologic function, reducing immune complex sedimentation in a kidney tissue of the mouse with the lupus and improving a kidney function of the mouse with the lupus, and effects of protecting a spleen function of the mouse with the lupus, protecting a vascular endothelium function of the mouse with the lupus, reducing blood pressure and improving vascular activity of the mouse with the lupus.The coptisine is a monomeric compound extracted from a common traditional Chinese medicine, namely rhizoma coptidis, has the advantages of low toxicity, simple extraction technology and the like, is wide in raw material resource, has good application and development prospects and is a relatively perfect novel traditional Chinese medicine monomer for treating the SLE, and the complications of the SLE such as immune dysfunction, lupus nephritis, lupus spleen injury, lupus atherosclerosis and lupus hypertension.
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI

Methods of diagnosing, monitoring treatment and treating systemic lupus erythematosus (SLE)

A method of treating systemic lupus erythematosus (SLE) in a subject are provided. The method comprise altering in cells of the subject activity and / or expression of at least one gene selected from the group consisting of Mpo, Ltf, Lcn, Camp, Ngp, Slfn, Ctsg, Thbs1, S100a8, 1190003K14Rik, Prtn3, S100a9, Tfpi, Fzd6, Nid1, 5830484A20Rik, 5830484A20 LOC 545340, Tnfsf4, IPstpip2, Pigr, 270022B06Rik, L5R-alpha, A130040M12Rik, Gpr132, Cd8b1, Dhx9, Cyp11a1, Lmo7, Rnf184, Pstpip2, Hdgfrp3, Ass1 and Zbtb20, thereby treating SLE. Also provided are methods of diagnosing SLE and monitoring treatment of SLE.
Owner:YEDA RES & DEV CO LTD

Traditional Chinese medicine composition for treating systemic lupus erythematosus

The invention discloses a traditional Chinese medicine composition for treating systemic lupus erythematosus, which comprises the following raw materials in parts by weight: 8-10 parts of astragalus, 2-4 parts of prepared rehmannia root, 6-7 parts of rhizoma anemarrhenae, 4-6 parts of scutellariae barbatae, 2-4 parts of radix clematidis, 1-3 parts of semen lepidii, 5-6 parts of calyx kaki, 2-4 parts of cornus officinalis, 6-8 parts of radix aconiti preparata, 4-6 parts of selfheal, 1-3 parts of rhzizoma drynariae, 2-4 parts of Japanese raspberry root, 5-7 parts of caulis spatholobi, 4-5 parts of straight ladybell root, 2-4 parts of radix polygonati officinalis, 6-8 parts of atractylodes macrocephala, 2-5 parts of medicated leaven, 1-3 parts of ampelopsis grossedentata and 3-4 parts of chinquapin bark and leaf. The traditional Chinese medicine composition adopts purely natural traditional Chinese medicines as raw materials, and achieves the effects of removing toxin, eliminating spots, tonifying the heart and spleen, tonifying qi and yin, warming the kidneys, tonifying Yang, strengthening the spleen, soothing the liver and the like through the combination of the traditional Chinese medicines, and has a good curative effect on systemic lupus erythematosus. Clinical trials prove that the effective rate of the traditional Chinese medicine composition is up to 99% and the recovery rate of the traditional Chinese medicine composition is up to 94.2%.
Owner:刘倩

Chinese medicine for treating systemic lupus erythematosus and preparation thereof

The invention relates to a Chinese medicine for treating the systemic lupus erythematosus, particularly the lupus nephritis and a method for preparing the same. The medicine consists of the following components of oldenlandia diffusa, barbat skullcap, redroot gromwell, glutinous rehmannia, root of red-rooted salvia, motherwort and scorpion. The medicine has effects of clearing away the heat-evil and expelling superficial evils and activating blood circulation to dissipate blood stasis and is mainly used to treat the systemic lupus erythematosus, particularly the lupus nephritis; moreover, by matching Western medicines such as glucocorticoid and immunodepressant, etc., the medicine can be used to jointly treat the systemic lupus erythematosus, which can improve the effect of the hormone and the immunodepressant in curing the systemic lupus erythematosus, lower the incidence rate of infecting the complication, lower the recurernce rate and the death rate and have the important clinical meaning. The medicine of the invention can be made in all medicament forms for clinical use, including the powder, the medicinal broth, the mixture, the oral taking liquid, the capsule, the pelletized granule and the concentrated pill, etc.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Application of arctigenin to preparing medicaments for treating systemic lupus erythematosus

The invention belongs to medicine field, and specifically relates to an application of arctigenin to preparing medicaments for treating systemic lupus erythematosus (SLE). Arctigenin is capable of effectively lymphocyte dysfunction of SLE mise and secretion unbalance of multiple cytokines, has substantial treatment effect on systemic lupus erythematosus, and has the potential of being exploited into the medicaments for treating systemic lupus erythematosus.
Owner:LUNAN PHARMA GROUP CORPORATION

Detection kit for early diagnosis of systemic lupus erythematosus

The invention provides a kit for detection of 3 SNP mutation loci, i.e. rs3813946 of the human CR2 gene 5' UTR region and rs17615 and rs104897 on a tenth exon. The kit can be applied in early diagnosis of systemic lupus erythematosus (SLE), and can realize early discrimination of SLE by detection of patients' genotype combination on a molecular level. The method provided by the invention is a sequencing genotyping method, has an accuracy rate up to 99.9%, and is easy for wide use and popularization.
Owner:SHANGHAI QY BIOTECH CO LTD

Composition for estimating risk of onset of systemic lupus erythematosus, comprising primer for detecting dna copy number variation in 1q25.1(RABGAP1L) location, 6P21.32 (c4) location and 10.q21.3 location

The present invention relates to a composition for a systemic lupus erythematosus risk prediction. In detail, in case where copy number variants of 1q25.1, C4 and 10q21.3 loci occur, the variants are regarded as high-risk groups for a systemic lupus erythematosus through the composition. The composition of the present invention enables prediction for the risk of systemic lupus erythematosus as the copy number variants of the three loci have a synergy effect for a development of systemic lupus erythematosus. Furthermore, the present invention is a test-friendly method which reduces analytical errors which may be created due to a new equipment purchased or technological limitations as a PCR generally implemented in a inspection room of majority of hospitals is used. In addition, the present invention is able to apply a non-invasive method to a person to be tested. Ultimately, the present invention predicts the risk of systemic lupus erythematosus which will essentially contribute to delaying development of the disease or to preventing an aggravation of state.
Owner:ザカソリックユニバーシティーオブコリアインダストリーアカデミックコーポレーションファウンデーション
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products